All manufacturers participating in the first cycle of Medicare drug price negotiations have responded with counteroffers, according to the Department of Health and Human Services. 

The news comes after HHS sent initial offers on February 1, as the agency was empowered to do by the Inflation Reduction Act, the White House’s attempt at lowering drug costs. The law is a cornerstone of the Biden Administration’s efforts on that front.